Short-term Treatment with Celecoxib May Prove to Bring Advantages in Preventing Gastric Carcinogenesis
In 1983 scientists managed to isolate and grow the H. pylori (Helicobacter pylori). Since then it was found that this bacteria represents an essential factor in triggering health conditions such as peptic ulcer, gastritis and gastric cancer.
The COX-2 (Cyclooxgenase-2) represents an enzyme which synthesizes prostaglandin. An evolved expression of Cyclooxgenase-2 is found in a great variety of malignant tumors affecting human beings which also comprise the gastric cancer. Experiments done on animals revealed that a long-term treatment with medication that inhibits the gastric carcinogenesis related to Cyclooxgenase-2. However, using such inhibiting drugs on humans is still not done due to the fact that the medication can trigger harmful and even fatal cardiovascular side-effects. This is why it is of great importance to discover the best and harmless therapy comprising Cyclooxgenase-2 inhibiting medications that also inhibit the Helicobacter pylori linked to gastric carcinogenesis.
A recent study regarding this matter was released in the World Journal of Gastroenterology in the October edition. Professor Wu coming from the Department of Gastroenterology within the Kaohsiung Medical University Hospital was the leader of the investigation. He utilized the Mongolian gerbil model in order to observe the best point of Cyclooxgenase-2 inhibiting medication for inhibiting gastric carcinogenesis produced by Helicobacter pylori. This new research also takes a closer look at the chemotherapy use for preventing this condition and also at the adverse effects the Cyclooxgenase-2 inhibiting medication may produce to the human body.
Earlier investigations utilized chemotherapies on a long-run basis for preventing the gastric carcinogenesis. Nonetheless, the Cyclooxgenase-2 inhibiting drugs did not come in placebo format and affected the patients. This group of medications must not be utilized on a long-run basis in the chemoprevention of the gastric malignant tumors.
As the investigation pointed, Celecoxib is a drug which might trigger anti-oncogenic effects. It can also inhibit the angiogenesis and the spreading of malignant tumors in the whole body. Moreover, this medication proved to be efficient in obtaining these effects either if it was used on a short- or a long- term basis. Celecoxib acted as a guardian who connotes an early oncogenic stage and not an inflammatory one. In addition, the utilization on short-term of Celecoxib proved to bring harmless inflammations and also stopped the spreading of gastric malignant cells in the organism.
If we were to listen to what the investigation has to say, the short- and long-term use of Celecoxib for counteracting Helicobacter pylori` infection pathway in a medical case is the best thing to do. This finding has been never present in earlier researches. Thus, the new discovery is essential in diminishing the adverse effects produced by Cyclooxgenase-2 inhibiting drugs.
The team of investigators state that Cyclooxgenase-2 inhibiting medication might be utilized as a chemoprevention treatment for patients that are 40 years or older. This approach may prove to play an essential part in the life of patients who suffer from extended metaplastic gastritis with an enhanced predisposition of developing gastric malignant tumors. Moreover, the therapy is essential also for people who suffer from refractory Helicobacter pylori infections with an increased predisposition for gastric malignant tumors.
As a gastroenterological specialist stated the research outcome provides new insights into a customized treatment against gastric malignant tumors starting with the prevention phase and also it may bring advantages for medical therapy in the near future.
.
